Table 2

Correlation between MDR1 polymorphisms and increased lymphoid infiltration in tumours

Exon	Genotype (polymorphism)	Amino acid change	No (%) of tumours with specific genotype (polymorphism)/No of tumours analysed	No (%) of tumours with specific genotype (polymorphism) and lymphoid infiltration	p*
NS=not significant.
*Using the χ² test, the proportions of tumours with lymphoid infiltration were compared among different alleles within the same locus (exon).
†Polymorphism previously described by Stein et al.²⁰
‡Polymorphism previously described by Hoffmeyer et al.²¹
§Polymorphism previously described by Mickley et al.²²
Promoter	†Promoter +8 T/T		313/327 (96%)	152/313 (49%)
Promoter	Promoter +8 T/C	Non-coding	14/327 (4%)	9/14 (64%)	0.036

Intron 1b	IVS1-81 (G)₄		311/327 (95%)	149/311 (48%)
Intron 1b	IVS1-81 (G)₄/(G)₃	Non-coding	16/327 (5%)	12/16 (75%)	0.010

Intron 1b	‡IVS-1 G/G		271/317 (85%)	127/271 (47%)
Intron 1b	IVS-1 G/A		45/317 (14%)	27/45(60%)	NS
Intron 1b	IVS-1 A/A	Non-coding	1/317 (<1%)	1/1 (100%)	NS

2	‡61 A/A		266/321 (83%)	125/266 (47%)
2	61 A/G	Asn21Asp	51/321 (16%)	29/51 (57%)	NS
2	61 G/G		4/321 (1%)	2/4 (50%)	NS

Intron 4	‡IVS4-25 G/G		44/63 (70%)	19/44 (43%)
Intron 4	IVS4-25 G/T	Non-coding	15/63 (24%)	7/15 (47%)	NS
Intron 4	IVS4-25 T/T		4/63 (6%)	2/4 (50%)	NS

11	1199 G/G		307/327 (94%)	152/307 (50%)
11	1199 G/A	Ser400Asn	20/327 (6%)	11/20 (55%)	NS

12	‡1236 C/C		81/327 (25%)	39/81 (48%)
12	1236 C/T	No change	163/327 (50%)	80/163 (49%)	NS
12	1236 T/T		83/327 (25%)	42/83 (51%)	NS

Intron 16	IVS16+158 G/G		82/87 (94%)	41/82 (50%)
Intron 16	IVS16+158 G/A	Non-coding	5/87 (6%)	3/5 (60%)	NS

21	§2677 G/G		14/41 (34%)	7/14 (50%)
21	2677 G/T	Ala893Ser	17/41 (41%)	7/17 (41%)	NS
21	2677 T/T		10/41 (24%)	4 /10 (40%)	NS

26	‡3435 C/C		44/159 (28%)	18/44 (41%)
26	3435 C/T	No change	85/159 (53%)	46/85 (54%)	NS
26	3435 T/T		30/159 (19%)	15/30 (50%)	NS